TW200800958A - N-substituted-azacyclylamines as histamine-3 antagonists - Google Patents

N-substituted-azacyclylamines as histamine-3 antagonists

Info

Publication number
TW200800958A
TW200800958A TW096108558A TW96108558A TW200800958A TW 200800958 A TW200800958 A TW 200800958A TW 096108558 A TW096108558 A TW 096108558A TW 96108558 A TW96108558 A TW 96108558A TW 200800958 A TW200800958 A TW 200800958A
Authority
TW
Taiwan
Prior art keywords
histamine
azacyclylamines
antagonists
substituted
receptor
Prior art date
Application number
TW096108558A
Other languages
English (en)
Chinese (zh)
Inventor
Derek Cecil Cole
Magda Asselin
Joseph Raymond Stock
Albert Jean Robichaud
Ji-In Kim
William Ronald Solvibile
Jonathan Laird Gross
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200800958A publication Critical patent/TW200800958A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW096108558A 2006-03-15 2007-03-13 N-substituted-azacyclylamines as histamine-3 antagonists TW200800958A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78251306P 2006-03-15 2006-03-15
US85907906P 2006-11-15 2006-11-15

Publications (1)

Publication Number Publication Date
TW200800958A true TW200800958A (en) 2008-01-01

Family

ID=38353957

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096108558A TW200800958A (en) 2006-03-15 2007-03-13 N-substituted-azacyclylamines as histamine-3 antagonists

Country Status (11)

Country Link
US (1) US7820825B2 (OSRAM)
EP (1) EP1994022A2 (OSRAM)
JP (1) JP2009530274A (OSRAM)
AR (1) AR059905A1 (OSRAM)
AU (1) AU2007227681A1 (OSRAM)
BR (1) BRPI0709612A2 (OSRAM)
CA (1) CA2645731A1 (OSRAM)
MX (1) MX2008011791A (OSRAM)
PE (1) PE20071023A1 (OSRAM)
TW (1) TW200800958A (OSRAM)
WO (1) WO2007108936A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097751A2 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
CN101511807A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 组胺h3受体的取代的苯甲酰胺调节剂
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
KR20100020487A (ko) * 2007-05-24 2010-02-22 와이어쓰 엘엘씨 히스타민-3 길항제로서 아자시클릴벤즈아미드 유도체
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
KR101546712B1 (ko) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. 히스타민 ｈ3 수용체의 조절제로서 사이클로알킬옥시- 및 헤테로사이클로알킬옥시피리딘 화합물
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
RU2537847C2 (ru) * 2009-06-26 2015-01-10 Санофи Новые фумаратные соли антагониста гистаминового рецептора н3
US8796247B2 (en) 2011-01-25 2014-08-05 Kissei Pharmaceutical Co., Ltd. Indole derivative, and pharmacologically acceptable salt thereof
ES2657912T3 (es) 2012-07-17 2018-03-07 Glaxosmithkline Intellectual Property (No. 2) Limited Indolcarbonitrilos como moduladores selectivos de los receptores de andrógenos
AU2016276316B2 (en) 2015-06-09 2020-01-23 Abbvie Inc. Nuclear receptor modulators
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
AU7759591A (en) 1990-04-13 1991-11-11 Smithkline Beecham Corporation Substituted benzimidazoles
KR100238346B1 (ko) 1993-04-07 2000-03-02 오쓰까 아끼히꼬 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
CA2287984A1 (en) 1997-05-01 1998-11-05 Gerald Floyd Smith Antithrombotic agents
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
DE60138605D1 (de) 2000-03-31 2009-06-18 Ortho Mcneil Pharm Inc Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
BRPI0408365B8 (pt) 2003-03-14 2021-05-25 Avidex Ltd compostos heterocíclicos de imunomodulação
CN1960969B (zh) * 2004-04-01 2012-03-28 伊莱利利公司 组胺h3受体药物、其制备方法及治疗用途
EP2261226B1 (en) 2004-05-14 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for preparing aurora kinase inhibitors
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
ES2325865T3 (es) 2004-07-26 2009-09-22 Eli Lilly And Company Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.
JP4942654B2 (ja) 2004-08-23 2012-05-30 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
CA2579889A1 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101107231A (zh) 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
CA2649913A1 (en) * 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
AR059905A1 (es) 2008-05-07
BRPI0709612A2 (pt) 2011-07-19
AU2007227681A1 (en) 2007-09-27
MX2008011791A (es) 2008-09-25
WO2007108936A3 (en) 2007-11-01
EP1994022A2 (en) 2008-11-26
PE20071023A1 (es) 2007-10-03
US20070219240A1 (en) 2007-09-20
CA2645731A1 (en) 2007-09-27
JP2009530274A (ja) 2009-08-27
WO2007108936A2 (en) 2007-09-27
US7820825B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
ME01532B (me) Jedinjenja
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
MX2009004822A (es) Compuestos de fenilpropionamida y usos de los mismos.
MX2009008284A (es) Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides.
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
IL206359A0 (en) Sulfonamides as orexin antagonists
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
DE602008002598D1 (en) Cyclohexylderivate
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de